{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:27:05Z","timestamp":1790731625689,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to analyze publicly available information about patient harm associated with an iontophoretic sumatriptan patch, to identify what went wrong and to suggest ways in which similar problems might be prevented in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Zecuity\u00ae sumatriptan iontophoretic transdermal system was marketed for acute treatment of migraine. The patch was withdrawn less than 10 months after its introduction because of multiple reports of scarring and burning. As of 2018, the FDA Adverse Event Reporting System public dashboard lists a total of 2889 reports of safety problems with the patch, 904 of which were classified as serious.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For this narrative review, we examined US Food and Drug Administration documents related to the new drug application for this product and its approval. We searched Clinicaltrials.gov, PubMed, Google, Facebook, Twitter, and Instagram public posts for relevant information relating to the patch, its approval, marketing, and complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FDA knew about problems with burns and scarring prior to approval of the product, and turned down the initial new drug application for this reason and because of other quality problems with the patch. The reapplication was approved despite continued concerns of several FDA reviewers about safety. The approval required the manufacturer to comply with enhanced postmarketing safety reporting. However, product information and labeling did not mention the possibility of burns or scarring. Approval was based on 1 clinical trial and 2 open label studies in which reporting of adverse events was suboptimal. The clinical trials had been prospectively registered but outcomes had been changed around the time the trial concluded. Aggressive marketing efforts and social media activity may have contributed to inaccurate perceptions of safety and efficacy, but social media also provided a written and photographic record of burns and other harm suffered by patients who used the patch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our review identified several problems with the development, testing, approval, and marketing of the Zecuity patch. To improve the process of developing headache treatments, it is important to consider the lessons that can be drawn from an examination of this high\u2010profile failure of the drug development and regulatory system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13424","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T13:08:42Z","timestamp":1540645722000},"page":"1639-1657","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process"],"prefix":"10.1111","volume":"58","author":[{"given":"Elizabeth W.","family":"Loder","sequence":"first","affiliation":[{"name":"Division of Headache, Department of Neurology Brigham and Women\u2019s Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Rayhill","sequence":"additional","affiliation":[{"name":"Headache Division, Department of Neurology State University of New York Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Burch","sequence":"additional","affiliation":[{"name":"Graham Headache Center, Department of Neurology, Brigham and Women\u2019s Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Teva announces voluntary suspension of marketing for ZECUITY\u00ae in the U.S.https:\/\/www.tevapharm.com\/news\/teva_announces_voluntary_suspension_of_marketing_for_zecuity_in_the_u_s_06_16.aspx. Accessed April 18 2018."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01600.x"},{"key":"e_1_2_10_4_1","unstructured":"Drugs@FDA: FDA approved drug products.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed April 7 2018."},{"key":"e_1_2_10_5_1","unstructured":"OpenTrials OpenTrialsFDA \u2013 An OpenTrials App"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0385-6"},{"key":"e_1_2_10_7_1","unstructured":"An exhaustive study of twitter users across the world.https:\/\/www.beevolve.com\/twitter-statistics\/. Accessed April 7 2018."},{"key":"e_1_2_10_8_1","unstructured":"GEN Teva outbids endo acquires NuPathe for $144M+ | GEN"},{"key":"e_1_2_10_9_1","unstructured":"News\u2010Medical.net Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine"},{"key":"e_1_2_10_10_1","unstructured":"ZECUITY\u00ae (sumatriptan iontophoretic transdermal system).https:\/\/dev.zecuity.com\/hcp\/information\/instructions-for-use.aspx. Accessed April 7 2018."},{"key":"e_1_2_10_11_1","unstructured":"Evaluation CFD. NDA20278\u20100\u2010Approval. OpenTrialsFDA.https:\/\/assets.documentcloud.org\/documents\/3157720\/NDA202278-0-Approval-Other-Review.pdf. Accessed April 7 2018."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587750-000000000-00000"},{"key":"e_1_2_10_13_1","unstructured":"https:\/\/assets.documentcloud.org\/documents\/3157571\/NDA202278-0-Approval-Medical-Review.pdf. Accessed April 20 2018."},{"key":"e_1_2_10_14_1","unstructured":"Wikipedia contributors. Prescription Drug User Fee Act. Wikipedia The Free Encyclopedia.https:\/\/en.wikipedia.org\/w\/index.php?title=Prescription_Drug_User_Fee_Act&oldid=811470746. Published November 21 2017. Accessed April 21 2018."},{"key":"e_1_2_10_15_1","article-title":"Teva\u2019s suspension of marketing for zecuity product is likely to have little impact","author":"Lee AM","journal-title":"TheStreet"},{"key":"e_1_2_10_16_1","unstructured":"Drugs.com Zecuity prices coupons & patient assistance programs \u2010 Drugs.com"},{"key":"e_1_2_10_17_1","unstructured":"MillerP.Zecuity patch recall illustrates risks of expedited approval | defective drug news.https:\/\/www.adrugrecall.com\/news\/zecuity-patch-recall-risks-expedited-approval\/. Accessed April 7. 2018."},{"key":"e_1_2_10_18_1","first-page":"20","article-title":"Zecuity redesign got migraine patch through FDA, but burning continued","volume":"78","author":"Sandburg B","year":"2016","journal-title":"Pink Sheet"},{"key":"e_1_2_10_19_1","unstructured":"Drugs@FDA FDA approved text for prescribing information for Zecuity"},{"key":"e_1_2_10_20_1","unstructured":"Zecuity.com Get help starting with ZECUITY\u00ae (sumatriptan iontophoretic transdermal system)"},{"key":"e_1_2_10_21_1","unstructured":"ZECUITY\u00ae couponterms and conditions.https:\/\/dev.zecuity.com\/coupon-terms. Accessed April 7 2018."},{"key":"e_1_2_10_22_1","unstructured":"ThemesO. FREE Zecuity migraine kit | MyFreeProductSamples.com.https:\/\/www.myfreeproductsamples.com\/new-offers\/free-zecuity-migraine-kit\/. Accessed April 7 2018."},{"key":"e_1_2_10_23_1","unstructured":"Zecuity.com Visit ZECUITY\u00ae (sumatriptan iontophoretic transdermal system)"},{"key":"e_1_2_10_24_1","article-title":"Zecuity skin patch effective in treating migraine","author":"Da Hee Han","journal-title":"Clin Pain Advis"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0706341"},{"key":"e_1_2_10_26_1","unstructured":"Migraine.com View all posts by. Zelrix migraine patch \u2010 FDA approval delayed"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0911-1024a"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00951.x"},{"key":"e_1_2_10_29_1","unstructured":"https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM506332.pdf. Accessed June 23 2018."},{"key":"e_1_2_10_30_1","volume-title":"US patent application 12\/181,142 \u2010 Google Search"},{"key":"e_1_2_10_31_1","unstructured":"April2018 \u2010 When do the ZECUITY patents expire and when will generic ZECUITY enter the market? Deep knowledge on small\u2010molecule drugs and the global patents covering them.https:\/\/www.drugpatentwatch.com\/p\/tradename\/ZECUITY. Accessed April 18 2018."},{"key":"e_1_2_10_32_1","unstructured":"Website.https:\/\/www.documentcloud.org\/documents\/3157571.html. Accessed April 18 2018."},{"key":"e_1_2_10_33_1","unstructured":"Marketwire NuPathe announces FDA acceptance of Zelrix NDA for filing"},{"key":"e_1_2_10_34_1","unstructured":"Marketwire NuPathe announces allowance of U.S. patent application for its migraine patch"},{"key":"e_1_2_10_35_1","unstructured":"Vitor Baptista (open. NDA202278\u20100\u2010Approval\u2010Cross Discipline Team Leader Review).https:\/\/www.documentcloud.org\/documents\/3157553-NDA202278-0-Approval-Cross-Discipline-Team.html. Accessed April 18 2018."},{"key":"e_1_2_10_36_1","unstructured":"Vitor Baptista (open. NDA202278\u20100\u2010Approval\u2010Medical Review).https:\/\/www.documentcloud.org\/documents\/3157571-NDA202278-0-Approval-Medical-Review.html. Accessed April 21 2018."},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","unstructured":"\u201cLiving drug\u201d may soon be approved by the FDA for treatment of acute lymphoblastic leukaemia.Pharm J.2017. doi:https:\/\/doi.org\/10.1211\/pj.2017.20203261.","DOI":"10.1211\/PJ.2017.20203261"},{"key":"e_1_2_10_38_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2013\/202278Orig1s000ltr.pdf. Accessed April 21 2018."},{"key":"e_1_2_10_39_1","unstructured":"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1100962\/000104746913011365\/a2217816zex-99_a5e.htm. Accessed April 21 2018."},{"key":"e_1_2_10_40_1","unstructured":"Exhibit EX\u201099.1.https:\/\/www.sec.gov\/Archives\/edgar\/data\/818686\/000130901414000042\/exhibit1.htm. Accessed April 21 2018."},{"key":"e_1_2_10_41_1","unstructured":"https:\/\/www.marketresearch.com\/product\/sample-8141683.pdf. Accessed April 21 2018."},{"key":"e_1_2_10_42_1","unstructured":"Zecuity.com Considering ZECUITY\u00ae (sumatriptan iontophoretic transdermal system)?"},{"key":"e_1_2_10_43_1","unstructured":"RobertT.Migraine Sumatriptan Patch Zecuity launched \u2010 migraine | HealthCentral. HealthCentral.https:\/\/www.healthcentral.com\/article\/migraine-sumatriptan-patch-zecuity-launched. Published August 28 2015. Accessed April 21 2018."},{"key":"e_1_2_10_44_1","unstructured":"Evaluation CFD research. Drug safety and availability \u2010 FDA drug safety communication: FDA evaluating the risk of burns and scars with zecuity (sumatriptan) migraine patch.https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm504588.htm. Accessed April 21 2018."},{"key":"e_1_2_10_45_1","unstructured":"https:\/\/pink.pharmaintelligence.informa.com\/-\/media\/supporting-documents\/pink-issue-pdfs\/p160926.pdf?la=en. Accessed April 21 2018."},{"key":"e_1_2_10_46_1","unstructured":"FDA Drug Shortages.https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Sumatriptan+%28ZECUITY%C2%AE%29+Iontophoretic+Transdermal+System&st=d&tab=tabs-4&panels=0&elqTrackId=2a866a4bf188491eb64b10c580f36548&elq=bffd55f57fba49efb3c571a622bdbf0b&elqaid=950&elqat=1&elqCampaignId=500. Accessed April 21 2018."},{"key":"e_1_2_10_47_1","unstructured":"MillerP.Zecuity lawsuit | zecuity migraine patch recall information.https:\/\/www.adrugrecall.com\/zecuity\/. Accessed April 21 2018."},{"key":"e_1_2_10_48_1","unstructured":"Zecuity class action lawsuit | migraine patch burn lawsuits.https:\/\/www.classactionlawsuithelp.com\/zecuity-class-action-lawsuit\/. Accessed April 21 2018."},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02198.x"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02094.x"},{"key":"e_1_2_10_51_1","unstructured":"https:\/\/assets.documentcloud.org\/documents\/3157571\/NDA202278-0-Approval-Medical-Review.pdf. Accessed April 18 2018."},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1039"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:41:57Z","timestamp":1762069317000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/head.13424"],"URL":"https:\/\/doi.org\/10.1111\/head.13424","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"2018-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}